PPT1 and retinal disorder: Gene therapy studies done by Griffey et al. utilized AAV serotype-2 (AAV2) to treat Ppt1−/− mice; collectively these studies illustrated that AAV-2 increased PPT-1 activity, reduced levels of autofluorescence, improved retinopathy and eliminated some behavioral phenotypes [36–38].